Opendata, web and dolomites

VITAL SIGNED

Vaccines and Infectious Diseases in the Ageing PopuLation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "VITAL" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

Organization address
address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX
website: www.umcutrecht.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 12˙427˙217 €
 EC max contribution 5˙499˙882 € (44%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-12-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) coordinator 781˙750.00
2    RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU NL (BILTHOVEN) participant 1˙977˙721.00
3    ACADEMISCH ZIEKENHUIS GRONINGEN NL (GRONINGEN) participant 363˙750.00
4    FOLKEHELSEINSTITUTTET NO (OSLO) participant 348˙472.00
5    FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA ES (VALENCIA) participant 291˙423.00
6    UNIVERSITAET INNSBRUCK AT (INNSBRUCK) participant 263˙750.00
7    SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG HU (BUDAPEST) participant 230˙976.00
8    UNIVERSITA DEGLI STUDI DI FERRARA IT (FERRARA) participant 230˙625.00
9    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 230˙000.00
10    STATENS SERUM INSTITUT DK (KOBENHAVN S) participant 206˙936.00
11    UNIVERSITE JEAN MONNET SAINT-ETIENNE FR (SAINT ETIENNE) participant 200˙000.00
12    P95 CVBA BE (LEUVEN) participant 186˙375.00
13    ISTITUTO SUPERIORE DI SANITA IT (ROMA) participant 90˙602.00
14    MIHAJLOVIC JOVAN RS (NOVI SAD) participant 60˙000.00
15    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 12˙500.00
16    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 12˙500.00
17    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 12˙500.00
18    BIOMERIEUX SA FR (Marcy l'Etoile) participant 0.00
19    FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES BE (BRUXELLES) participant 0.00
20    GLAXOSMITHKLINE BIOLOGICALS SA BE (RIXENSART) participant 0.00
21    JANSSEN VACCINES & PREVENTION BV NL (LEIDEN) participant 0.00
22    MERCK SHARP & DOHME CORP US (WHITEHOUSE STATION NJ) participant 0.00
23    PFIZER LIMITED UK (SANDWICH) participant 0.00
24    SANOFI PASTEUR SA FR (LYON) participant 0.00

Map

 Project objective

Today’s major challenge is to improve efficacy of vaccines to protect the growing ageing population against infectious diseases (ID). The VITAL project aims to address this challenge by assessing the ID burden and mechanisms of immunosenescence to provide evidence-based knowledge on vaccination strategies to establish healthy ageing. Links with existing projects containing data sources combined with novel data acquired through our extensive network of dataregistries across Europe will result in a database of epidemiology, risk factors and burden of disease of both vaccine-preventable (VP) and potential vaccine-preventable ID. Crucial knowledge on factors that hamper immune responsiveness and in-depth analyses of immune compartments involved in inducing effective immune responses to different vaccines in the ageing host will be gathered. We will identify novel predictive, potentially universal immune profiles of vaccine responses using novel technologies, unique experimental models and (infection) cohorts of elderly subjects in which (bio)markers of frailty have already been identified. Novel strategies to address the problem of immunosenescence will be tested, in particular whether vaccination of middle-aged individuals can maintain proper memory immune responses in the elderly, to improve memory immunity before reaching old age. Using data on epidemiology of VPID and immune responsiveness, novel agent-based models will be developed to build a user-friendly tool to be used by health care professionals for optimal implementation of vaccination strategies for older people and to develop dissemination protocols for the obtained knowledge for the health care field. Finally, we will deliver a framework that forms the basis for designing, implementing and regularly updating vaccination schemes for the ageing population. Thereby, VITAL will initiate an important impetus to a more targeted immunization program for the elderly in Europe that will enhance healthy aging.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VITAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VITAL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More